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diastolic blood pressure were 130.14 mmHg and 73.48 mmHg respectively. Inci-
dences of co-morbidities was as follow: ischemic heart disease in 49.3%, arterial
hypertension in 34.12%, diabetes in 28.03%, atrial fibrillation in 9.94% and renal
insufficiency in 8.55%. In 60.7% of patients we measured blood pressure below
140/90 mmHg (mean 116.94/70.4 mmHg) while in 39.9% blood pressure was
higher than 140/90 mmHg (mean 159.89/101.14 mmHg). Average blood pressure
differed significantly (p<0.001) between two groups. There was a significantly dif-
ference on prescript of ACE inhibitors (76.09% vs 57.33%), beta blockers (70.3%
vs 52.78%), calcium channel blockers (4.69% vs 17.02%) and digoxine (2.94% vs
1.68%). Patients with lowest blood pressure were less often treated with furo-
semide (28.33% vs 45.63%, p<0.05) but more often with spironolactone (55.78%
vs 32.37%, p<0.05).
Conclusions: The management of blood pressure in chronic heart failure is
very important and due to an adequate and optimal pharmacological treatment.
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Purpose: Hyperuricemia could be a valid prognostic marker and useful for
metabolic, hemodynamic, and functional staging in chronic heart failure. hyper-
uricemia is associated with deleterious effects on endothelial dysfunction, oxida-
tive metabolism, platelet adhesiveness, hemorheology, and aggregation
Methods: The purpose of this study was to determine association between
hyperuricemia and prognosis in 1509 patients with chronic heart failure,
during median follow-up of 32 months. Chi2 test was used, a difference was
statistically considered significant if p<0.05.
Results: The prevalence of hyperuricemia was 10.73% (162), the mean age
was 64.62 years (37-100) with a male predominance (64.81%). The mean
ejection fraction was 32.47%. Thirty eight percent patients have hypertension
and 21.6% have diabetes. There was a correlation between hyperuricemia and
severity of heart failure compared with normouricemia evaluated by: NYHA
functional class, [75,72% patients with hyperuricemia were in class II vs
61.03% for normouricemia (p= 0.0093), 35,69% in class III vs 25.03%
(p=0.0095) and 4.98% in class IV vs 2.09% (p=0.0091)], renal dysfunction:
mean creatinine was at 16.25 for hyperuricemia vs 11 mg per litr for normou-
ricemia, use of diuretics 61.11% vs 40.46% (p=0.0059), congestive heart
failure in 24.07% vs 12.04% (p=0.0086)
Conclusions: High serum uric acid levels are a strong, independent marker
of impaired prognosis in patients with chronic heart failure
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Background: Heart failure (HF) patients are particularly susceptible to
electrolyte abnormalities and especially to hyperkalemia. Potassium (K) bal-
ance may be lost both through the neurohormonal mechanisms and through
the drugs used in the treatment of this illness. Both hypokalaemia and hyper-
kalaemia are associated with increased mortality, mainly due to a higher risk
of potentially fatal arrhythmia.
Our goal was to explore the incidence and predictors of hyperkalemia in a
broad population of heart failure patients.
Methods: This was a retrospective study of 1371 consecutive patients
admitted to the therapeutic unit for heart failure between May 2006 and Sep-
tember 2010. Patients on dialysis and those with an estimated glomular filtra-
tion rate (GFR)<10ml/min/1,73m² were excluded. Complete history on
admission, age, sex, body weight, physical findings, comorbidities, and labo-
ratory information were collected.
Results: The mean age of our population was 64.4 years (16-100), with a male
predominance (64.6%). In 18 patients (1.3%) K was <3.0 mmol/L, and in 424
patients (30.9%) K was >5.0 mmol/L. Independent of treatment assignment,
patients at highest risk for hyperkalemia were those with age 75 years (28.5%),
diabetes (33.9%), male gender (25.5%), high potassium at baseline (24.5%), renal
dysfunction (44.5%) (identified by creatinine 2 mg/dl or GFR 30 ml/min/1.73m²),
symptomatic HF (28.1%) and those receiving therapy with angiotensin-converting
enzyme (ACE) inhibitors (25.3%) or spironolactone (27.2%).
Conclusion: Changes in potassium ion may cause life-threatening arrhyth-
mias. The risk of hyperkalemia is increased in symptomatic heart failure
patients with comorbidities or combined renin-angiotensin-aldosterone system
(RAAS) blockade. A favorable balance of benefit and risk requires clinical
vigilance and closer laboratory monitoring, particularly among these patients.
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Background: Chronic Heart failure (CHF) has a poor prognosis. Most of right
ventricular (RV) echocardiographic variables measure only basal or annular RV
function. Global 2D strain, is used to detect the first signs of LV dysfunction. Our
hypothesis was that RV-2Dstrain, allowing to measure basal to apical RV lateral
wall systolic function, was lower in CHF than in controls and was a better pre-
dictor of cardiac events in CHF than other RV echo-variables.
Methods: 43 controls and 118 chronic heart failure patients with sinus
rhythm, optimal medication and stabilized at east for one month (CHF) were
prospectively enrolled from November 2005 to April 2008 in our CHF clinic.
All patients had a clinical, biological and echocardiographic assessment. 2D
RV strain and four chamber LV strain, left ventricle and left atria dimensions,
diastolic LV function, tricuspid annular plane excursion, peak systolic velocity
of the tricuspid annular using tissue Doppler imaging were assessed. The pri-
mary endpoint was death or urgent transplantation or ventricular assist device
or an acute heart failure episode.
Results: RV-2Dstrain was measurable in 39 controls (57.5±17.2 years,
50% men) with a median and 95% CI of: –30% (–39%; –20%). RV-2Dstrain
was measurable in 104 CHF, their age and left ventricular ejection fraction
mean +/– SD were 57.0±10.9 years and 28.8±8.2%. 80 % were men. RV-
2Dstrain mean and 95%CI in CHF was –19%(–34%; –9%). Prevalence of RV
dysfunction was 52% in CHF if –20% was used as threshold. During a mean+/
– SD follow-up of 37+/–14 months for the patients without events. 57 patients
reached the primary endpoint. On Cox proportional hazards multivariate anal-
ysis only RV-2Dstrain and logBNP were independent predictor of outcome.
The threshold of RV-2Dstrain defined using ROC curve was –21%. Patients
with RV-2Dstrain >–21% had the worse prognosis (X2-log-Rank test=14,
p<0.0001) than patient with RV-2Dstrain <–21%.
Conclusion: RV 2D strain is a strong independent predictor of outcome in
HF and appears to be superior to the other RV or LV systolic echocardio-
graphic variables.
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Biochemical marker testing has revolutionized the approach to diag-
nosis and management of heart failure (HF). Natriuretic peptides are rou-
tinely used, nevertheless better biomarkers are needed to improve
diagnosis and guide therapy. Applying proteomics to clinical samples from
patients with acute heart failure (AHF), Quiescin Q6 (QSOX1) emerged as
a promising marker to differentiate dyspnea caused by acute decompensated
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